[go: up one dir, main page]

BR112022022352A2 - Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos - Google Patents

Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos

Info

Publication number
BR112022022352A2
BR112022022352A2 BR112022022352A BR112022022352A BR112022022352A2 BR 112022022352 A2 BR112022022352 A2 BR 112022022352A2 BR 112022022352 A BR112022022352 A BR 112022022352A BR 112022022352 A BR112022022352 A BR 112022022352A BR 112022022352 A2 BR112022022352 A2 BR 112022022352A2
Authority
BR
Brazil
Prior art keywords
polypeptides
canine
bind
bind canine
vhh
Prior art date
Application number
BR112022022352A
Other languages
English (en)
Inventor
Pandit Rajay
C Timmer John
P Eckelman Brendan
Deveraux Quinn
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of BR112022022352A2 publication Critical patent/BR112022022352A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

POLIPEPTÍDEOS DE LIGAÇÃO À PD-1 CANINA E USOS DOS MESMOS. A presente invenção refere-se a polipeptídeos que contêm VHH que se ligam à PD-1 canina. Em algumas modalidades, são fornecidos polipeptídeos que contêm VHH que se ligam e antagonizam a PD-1 canina. Também são fornecidos usos dos polipeptídeos que contêm VHH.
BR112022022352A 2020-05-04 2021-05-03 Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos BR112022022352A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019817P 2020-05-04 2020-05-04
PCT/US2021/030476 WO2021225961A1 (en) 2020-05-04 2021-05-03 Canine pd-1-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
BR112022022352A2 true BR112022022352A2 (pt) 2023-01-10

Family

ID=76076497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022352A BR112022022352A2 (pt) 2020-05-04 2021-05-03 Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230331846A1 (pt)
EP (1) EP4146696A1 (pt)
JP (1) JP2023524995A (pt)
KR (1) KR20230005955A (pt)
CN (1) CN115776990A (pt)
AU (1) AU2021266688A1 (pt)
BR (1) BR112022022352A2 (pt)
CA (1) CA3177921A1 (pt)
MX (1) MX2022013840A (pt)
WO (1) WO2021225961A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
WO2024153949A1 (en) * 2023-01-20 2024-07-25 Petmedix Ltd Therapeutic antibodies
CN117343185B (zh) * 2023-12-06 2024-03-01 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP2771694A4 (en) * 2011-10-26 2015-08-05 Novartis Tiergesundheit Ag MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP3168236B1 (en) * 2014-07-09 2019-09-04 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine pd-1 antibody or anti-canine pd-l1 antibody
KR102357893B1 (ko) * 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
WO2020077257A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CN110194799B (zh) * 2019-06-03 2021-07-23 北京希诺谷生物科技有限公司 结合犬pd-1的抗犬pd-1抗体

Also Published As

Publication number Publication date
MX2022013840A (es) 2023-02-09
KR20230005955A (ko) 2023-01-10
CA3177921A1 (en) 2021-11-11
CN115776990A (zh) 2023-03-10
US20230331846A1 (en) 2023-10-19
JP2023524995A (ja) 2023-06-14
WO2021225961A1 (en) 2021-11-11
AU2021266688A1 (en) 2022-12-08
EP4146696A1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
BR112022022352A2 (pt) Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
FR23C1012I2 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
EP3370768A4 (en) SPECIFIC TO PD-1 BINDING ANTIBODIES AND THEIR USE
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
BR112022013878A2 (pt) Anticorpos que ligam integrina avb8 e utilizações dos mesmos
CO2020007244A2 (es) Inhibidores de kras g12c
CR20160090A (es) DIACUERPOS MONOVALENTES BIESPECÍFICOS QUE PUEDEN UNIRSE A gpA33 Y CD3, Y SUS USOS
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
EP3687564C0 (en) RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF
BR112021021048A2 (pt) Polipeptídeos que se ligam a cd33 e seus usos
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
CY1119154T1 (el) Anti-vla-4 αντισωματα
EP3419998A4 (en) CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
EP3877868A4 (en) Review response generation and review sentiment analysis
TR201821216T4 (tr) Ige-aracılı rahatsızlıkların tedavisine yönelik kompozisyonlar ve yöntemler.
TR201906690T4 (tr) Polipropilen Bazlı Isı-Eritmeli Yapışkan Bileşim
BR112016007707A2 (pt) método de ligação de material particulado, método de adesão em duas superfícies e composição
TR201908235T4 (tr) En az bi̇r bi̇leşeni̇ kompozi̇t materyali̇n i̇şlenecek bi̇r parçasi araciliğiyla oluşturulan ayri bi̇leşenleri̇n bi̇rbi̇ri̇ne bi̇rleşti̇ri̇lmesi̇ne yöneli̇k yöntem ve zimba perçi̇ni̇
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND USES THEREOF
MA52626A (fr) Anticorps anti-cd63, conjugués et leurs utilisations
BR112019005783A2 (pt) agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos
BR112023021034A2 (pt) Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INHIBRX BIOSCIENCES, INC. (US)